

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
03 December 2020 (03.12.2020)



(10) International Publication Number
WO 2020/239951 A1

(51) International Patent Classification:

A61P 11/00 (2006.01) *C07D 413/12* (2006.01)
A61P 11/14 (2006.01) *C07D 413/14* (2006.01)
C07D 239/94 (2006.01) *C07D 417/12* (2006.01)
C07D 401/12 (2006.01) *C07D 487/04* (2006.01)
C07D 403/12 (2006.01) *A61K 31/517* (2006.01)
C07D 405/12 (2006.01) *A61K 31/519* (2006.01)
C07D 409/12 (2006.01) *A61K 31/5355* (2006.01)
C07D 413/04 (2006.01) *A61K 31/5377* (2006.01)

SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2020/064913

(22) International Filing Date:

28 May 2020 (28.05.2020)

Published:

— with international search report (Art. 21(3))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

19177604.6 31 May 2019 (31.05.2019) EP
19201168.2 02 October 2019 (02.10.2019) EP

(71) Applicant: **CHIESI FARMACEUTICI S.P.A.** [IT/IT];
Via Palermo 26/A, 43122 Parma (IT).

(72) Inventors: **BRUNO, Paolo**; c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A, 43122 Parma (IT). **BIAGETTI, Matteo**;
c/o Chiesi Farmaceutici S.p.A. Via Palermo 26/A, 43122
Parma (IT). **FIGURELLI, Claudio**; c/o Chiesi Farmaceutici
S.p.A. Via Palermo 26/A, 43122 Parma (IT). **PIZZIRANI,
Daniela**; c/o Chiesi Farmaceutici S.p.A. Via Palermo 26/A,
43122 Parma (IT). **PALA, Daniele**; c/o Chiesi Farmaceuti-
ci S.p.A. Via Palermo 26/A, 43122 Parma (IT). **RONCHI,
Paolo**; c/o Chiesi Farmaceutici S.p.A. Via Palermo 26/A,
43122 Parma (IT). **BAKER-GLENN, Charles**; c/o Chiesi
Farmaceutici S.p.A. Via Palermo 26/A, 43122 Parma (IT).
VAN DE POËL, Hervé; c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A, 43122 Parma (IT). **HIRST, Kim**; c/o
Chiesi Farmaceutici S.p.A. Via Palermo 26/A, 43122 Par-
ma (IT).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS

(57) Abstract: The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are amino quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X₃ receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).

WO 2020/239951 A1